The Consortium gives it approval to publish this genome based on the information provided in the paper and the understanding that it is believed that ABM4 is a minor species and that it is considered that strategies targeting M1 will impact ABM4 as well. Given the ability to culture the organism easily in Broth is it routinely used to test vaccine and chemogenomics candiadate compounds? If It isnt why not ? 
As a precaustion We would support the inclusion of in vitro tests using this organism so taht we are well placed to identify if ABM4 will recall more specific strategies to mitigate its methane production.  I would appreciate a response to these notes.

Mark Aspin 